Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Revenue (2016 - 2025)

Historic Revenue for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $7.5 million.

  • Editas Medicine's Revenue rose 1226557.38% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year decrease of 2489.56%. This contributed to the annual value of $32.3 million for FY2024, which is 5863.7% down from last year.
  • Latest data reveals that Editas Medicine reported Revenue of $7.5 million as of Q3 2025, which was up 1226557.38% from $3.6 million recorded in Q2 2025.
  • Editas Medicine's 5-year Revenue high stood at $60.0 million for Q4 2023, and its period low was $42000.0 during Q3 2022.
  • In the last 5 years, Editas Medicine's Revenue had a median value of $6.2 million in 2021 and averaged $9.0 million.
  • In the last 5 years, Editas Medicine's Revenue crashed by 9932.23% in 2022 and then skyrocketed by 1260476.19% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Revenue stood at $12.5 million in 2021, then tumbled by 47.58% to $6.5 million in 2022, then soared by 818.74% to $60.0 million in 2023, then crashed by 49.03% to $30.6 million in 2024, then crashed by 75.35% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $3.6 million for Q2 2025, and $4.7 million during Q1 2025.